

**PATIENT DATA FOR PROSPECTIVE
PROSTATE CANCER STUDY**

AGE	PSA AT DIAGNOSIS	FOLLOW-UP PSA	% PSA DECREASE	PERIOD OF SURVEILLANCE	GLEASON SCORE	CLINICAL STAGE	PATHOLOGIC STAGE	IPSS-INDEX	IPSS CHANGE	EPS	EPS CHANGE
61	8.5 ng/ml	2.9 ng/ml	66%	64 months	5 (3+2)	T2c	T2c	5.5-2.5 = 3	55%	256-113	56%
68	7.0 ng/ml	2.8 ng/ml	60%	60 months	5 (3+2)	T1c	T2a	17.5-8.5 = 11	56%	85-15	82%
43	4.7 ng/ml	2.1 ng/ml	55%	30 months	6 (3+3)	T1c	T2a	4-0 = 4	100%	325-190	42%
65	11.7 ng/ml	7.6 ng/ml	35%	38 months	5(3+2)/6(3+3)	T1c	T2b				
64	2.9 ng/ml	1.5 ng/ml	48%	60 months	6 (3+3)	T1c	T2a				
55	2.1 ng/ml	3.0 ng/ml	+43%	34 months	5 (3+2)	T2c	T2c	6.5-2 = 4.5	69%	350-158	55%
56	7.3 ng/ml	4.2 ng/ml	42%	33 months	5(2+3)/6(3+3)	T2a	T2b	10.5-6 = 4.5	43%	TNTC-5	99%
70	6.9 ng/ml	5.1 ng/ml	26%	19 months	6 (3+3)	T2c	T2a	11.5-7.5 = 4	35%	268-17	94%
68	5.8 ng/ml	4.9 ng/ml	16%	31 months	6 (3+3)	T1c	T2a	4-0 = 4	100%		
56	9.1 ng/ml	4.9 ng/ml	46%	47 months	6 (3+3)	T1c	T2a	11-7 = 4	36%	375-150	60%
61	3.0 ng/ml	0.8 ng/ml	73%	24 months	5 (3+2)	T1c	T2a				
48	3.2 ng/ml	2.2 ng/ml	31%	13 months	6 (3+3)	T2a	T2b	9.5-2 = 7.5	79%		
69	6.2 ng/ml	3.2 ng/ml	48%	10 months	5 (3+2)	T1c	T1a				
56	4.4 ng/ml	1.9 ng/ml	57%	24 months	6(3+3)/7(3+4)	T2c	T2c	8.5-1.5 = 7	82%	350-30	91%
74	11.4 ng/ml	10.9 ng/ml	13%	28 months	6 (3+3)	T2b	T2b				
63	6.8 ng/ml	1.9 ng/ml	72%	33 months	5 (3+2)	T1c	T2a	5.5-2.5 = 3	55%	275-70	75%
71	6.6 ng/ml	4.7 ng/ml	29%	12 months	6 (3+3)	T1c	T2c				
64	14.4 ng/ml	1.9 ng/ml	87%	14 months	6 (3+3)	T1c	T2a				
70	8.4 ng/ml	3.0 ng/ml	64%	5 months	6 (3+3)	T1c	T2a				
72	4.4 ng/ml	5.0 ng/ml	+14%	11 months	6(3+3)/7(3+4)	T2b	T2c				
<hr/>											
TOTALS:	134.8 ng/ml	60.3 ng/ml	802	588							
	Mean Starting PSA	Mean PSA Change	Mean % Decrease	Mean Months					Mean % Change		Mean % Change
	6.7 ng/ml	3.0 ng/ml	40%	30					65%		73%

EPS = Expressed Prostatic Secretion (An Indication of Prostate Inflammation)

PSA = Prostate Specific Antigen

IPSS-Index = International Prostate Symptom Score

TNTC = Too Numerous to Count

Gleason Score: 2-10 (Primary Cancer Grade + Secondary Cancer Grade) with 2 being the most favorable and 10 being the worst

Ronald E. Wheeler, M.D.
October 2004